Anita Treohan
Profile
Anita Treohan is currently working as the VP-Clinical Development Operations at Avrobio, Inc. Previously, she worked as the Director-Clinical Operations at ImmusanT, Inc. She completed her graduate degree at Boston University and her undergraduate degree at Emory University.
Former positions of Anita Treohan
| Companies | Position | End |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | - |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Anita Treohan
| Emory University | Undergraduate Degree |
| Boston University | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Stock Market
- Insiders
- Anita Treohan
